InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$29.58

2026-10-16

Market Cap

$168.6B

Volume

28.6M

52-Wk High

$29.88

52-Wk Low

$23.62

Trailing PE

39.1

P/S

2.65

Gross Margin

71.3%

Net Margin

6.8%

ROE

5%

ROIC

9%

Piotroski

7/9

Altman Z

2.1

1-Yr Return

+24.2%

5-Yr Return

+21.1%

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$168.6BEmployees75,000 (SEC-filed)CEOAlbert BourlaIPO1972-06-01CountryUS

66 Hudson Boulevard East, New York City, NY 10001-2192 · Tel 212 733 2323 · pfizer.com

INSIDERSTREET SCORE46 / 100Street mean $30.50 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALNET BUYING$3.0M open-market purchases vs $0.1M sales / 6 mo

1 Year vs S&P 500 · PFE +24.2% · S&P 500 +15.9% · spread +8.3pp

7 Years vs S&P 500 · PFE +21.1% · S&P 500 +189.9% · spread -168.7pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE46of 100

Score Breakdown

Profitability	45/100
Growth	20/100
Momentum	55/100
Quality	73/100
Earnings Quality	71/100
Balance Sheet	43/100
Value	49/100
Risk (safety)	50/100
Overall	46.1/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
GILD	44
BMY	68
AMGN	67
AZN	71
NVS	65
MRK	49
PFE	46

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 71 in 25 Q2, latest 46 — -25 since. Dropped below the 55 line in 25 Q4, at 49. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY46 / 100IS Score 46.1 / 100 · -25.0 from peak of 71

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 90 / 100 · Power +80 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 46, price structure 90 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 46.1	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 67 → 49 → 52 → 46	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 3,009 → now 2,849	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score4 of 4top 0% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)3 buys2026-09-25

Insider Buys (180d)3$2.96M

ETF Funds (30d)1417 up / 1184 downnet +233 funds

Institutions Added (13F)-119managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 3,009 · latest 2,849 (-160 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	2,849	3866.4M	$91.8B	67.8%
2026 Q1	2,968	3761.6M	$108.8B	66.0%
2025 Q4	2,927	3733.9M	$92.6B	65.5%
2025 Q3	2,824	3630.3M	$91.6B	63.7%
2025 Q2	2,822	3733.7M	$90.8B	65.5%
2025 Q1	2,947	3759.8M	$97.2B	66.0%
2024 Q4	3,009	3754.8M	$99.5B	65.9%
2024 Q3	2,922	3767.5M	$109.1B	66.1%
2024 Q2	2,890	3745.8M	$104.7B	65.7%
2024 Q1	2,890	3803.5M	$105.2B	66.7%
2023 Q4	2,952	3876.6M	$113.5B	68.0%
2023 Q3	2,940	3911.1M	$131.2B	68.6%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Bourla Albert	director, Chairman & CEO	2026-10-15	A-Award	20	—	783,997
Bourla Albert	director, Chairman & CEO	2026-10-13	A-Award	71	—	783,981
Bourla Albert	director, Chairman & CEO	2026-09-30	A-Award	21	—	783,888
Buckley Mortimer J	director	2026-09-25	A-Award	1,308	—	28,040
Echevarria Joseph	director	2026-09-25	A-Award	1,613	—	169,739
Narayen Shantanu	director	2026-09-25	A-Award	1,744	—	205,649
Quincey James	director	2026-09-25	A-Award	1,352	—	90,671
Smith James C	director	2026-09-25	A-Award	1,570	—	187,210

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	2	5,278	$0.1M	Counted
P — Open-market purchases	3	114,863	$3.0M	Counted
M — Exercises (paired A/D)	6	783,792	$26.5M	None — mechanics
F — Tax withholding	16	770,414	$20.7M	None — compensation

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalNet Buying

Open-Market Sells$0.1M2 txns / 6 mo

Open-Market Buys$3.0M3 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2025-05-23	Dolsten Mikael	59,781	$1.4M
2025-05-05	Dolsten Mikael	55,000	$1.3M
2023-09-13	Pao William	54,379	$1.9M
Trailing 12 mo	0 filings	—	$0M

Filed	Form	Reporting person	% of class	Shares
2026-05-01	SCHEDULE 13G	Vanguard Capital Management	7.51%	427.4M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-25	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Ro Khanna	House	SELL	$15,001 - $50,000	2026-09-04	2026-10-09
Tommy Tuberville	Senate	SELL	$15,001 - $50,000	2026-06-08	2026-07-16
Thomas Hawley Tuberville	Senate	SELL	$15,001 - $50,000	2026-06-08	2026-07-16
Susan M. Collins	Senate	BUY	$15,001 - $50,000	2026-02-03	2026-03-25

House 12-Mo20 trades8 purchases

Senate 12-Mo4 trades2 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,968

13F Shares3.76B66.0% of shares out

New / Closed257 / 165positions, QoQ

Increased / Reduced1,311 / 1,090positions, QoQ

Put/Call (13F)0.78option positions

Free Float99.9%5.69B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	7.5M	$214M
Wealth Enhancement Advisory Servic	4.1M	$107M
Artemis Investment Management Llp	3.8M	$107M
Fort Washington Investment Advisor	2.1M	$59M
Fjarde Ap-Fonden /Fourth Swedish N	1.7M	$49M
Mn Services Vermogensbeheer B.V.	1.7M	$48M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.2%	$5.2B
VTI	0.2%	$5.2B
VSMPX	0.2%	$5.2B
VTSAX	0.2%	$5.2B
VFINX	0.2%	$4.3B
VFIAX	0.2%	$4.3B

13F Filers Holding PFE — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session42.8%2026-10-15

20-Day Avg46.4%50-day 42.6%

TrendRising20d vs 50d

By Market CenterQ: 43% · N: 52% · B: 31%latest session

Weekly Notional ($B)

Where PFE Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	37.6M	240 sh
Ubsa Ubs Ats	19.2M	199 sh
Ebxl Level Ats	18.1M	87 sh
Mstx Ms Trajectory Cross (Ats-1)	16.5M	246 sh
Bids Bids Ats	15.3M	1,418 sh
Pure Purestream	11.9M	74 sh

Where a dollar of Pfizer Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$37.1B	59%
Developed Rest Of World	$16.2B	26%
Emerging Markets	$9.3B	15%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

PFE (live moat model)Peer median: GILD · BMY · AMGN · AZN · NVS

Component scores from the live moat model. Peer median illustrative.

Moat score 60/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Albert Bourla	Chairman of the Board & Chief Executive Officer
Chris Boshoff FMedSci	Chief Scientific Officer and President of Research & Development
Aamir Malik	Executive Vice President & Chief U.S. Commercial Officer
Douglas Lankler	Executive Vice President & Chief Legal Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+23.9%

Next Report2026-11-03

Income Quality3.06OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+95.2%	+23.4%	-40.6%	+6.8%	-1.6%
Gross profit	+56.9%	+32.5%	-51.1%	+37.9%	+5.2%
Operating income	+128.9%	+80.6%	-85.9%	+211.5%	-6.3%
Net income	+141.8%	+41.6%	-93.2%	+276.0%	-3.1%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	81.3	100.3	59.6	63.6	62.6
Cost of revenue	34.4	38.2	29.2	21.8	18.6
Gross profit	46.9	62.1	30.3	41.8	44.0
R&D expense	13.8	11.4	10.6	10.7	12.0
SG&A expense	12.3	13.1	14.5	14.7	13.3
Operating income	20.8	37.5	5.3	16.5	15.4
EBITDA	30.8	41.0	9.6	18.1	15.1
D&A	5.2	5.1	6.3	7.0	4.9
Pretax income	24.3	34.7	1.1	8.0	7.5
Income tax	1.9	3.3	-1.1	-0.0	-0.3
Net income	22.1	31.4	2.1	8.0	7.8
Diluted EPS ($)	3.88	5.47	0.37	1.41	1.36
Diluted shares (M)	5,708	5,733	5,709	5,700	5,686

Operating CF$12B

CapEx$3B

Free cash flow$9B

SBC$0B

Buybacks$0B

Net cash change$0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.4	2.9	1.0	1.1
ST investments	22.3	9.8	19.4	12.5
Receivables (net)	14.5	15.5	14.8	11.9
Total current assets	51.3	43.3	50.4	42.9
PP&E (net)	16.3	18.9	18.4	21.5
Goodwill + intangibles	94.7	132.7	123.9	125.0
Total assets	197.2	226.5	213.4	208.2
Accounts payable	6.8	6.7	5.6	5.2
Short-term debt	2.9	10.3	6.9	3.5
Deferred revenue	2.5	2.7	1.5	0.8
Total current liabilities	42.1	47.8	43.0	37.0
Long-term debt	31.9	60.5	57.4	61.6
Total liabilities	101.3	137.2	124.9	121.4
Shareholders' equity	95.9	89.3	88.5	86.8

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	31.4	2.2	8.1	7.7
D&A	5.1	6.3	7.0	6.6
Stock-based compensation	0.9	0.5	0.9	0.0
Working capital change	(4.5)	(2.2)	(3.1)	(5.4)
Operating cash flow	29.3	8.7	12.7	11.7
Capital expenditures	(3.2)	(3.9)	(2.9)	(2.6)
Investing cash flow	(15.8)	(32.3)	2.7	(1.4)
Buybacks	(2.0)	0.0	0.0	0.0
Dividends paid	(9.0)	(9.2)	(9.5)	(9.8)
Debt issuance / (repay)	(3.5)	35.9	(7.2)	(0.1)
Financing cash flow	(14.8)	26.1	(17.1)	(10.3)
Free cash flow	26.0	4.8	9.8	9.1

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	31.7%	36.3%	2.3%	9.1%	8.9%	5%
ROA	13.2%	16.6%	1.0%	3.6%	3.7%	2.2%
ROIC	24.3%	31.9%	6.6%	12.8%	11.4%	9.3%
Gross margin	57.7%	61.9%	50.9%	65.8%	70.3%	71.3%
Operating margin	25.6%	37.4%	8.9%	25.9%	24.7%	25.1%
Net margin	27.2%	31.3%	3.6%	12.6%	12.4%	6.8%
EBITDA margin	37.9%	40.9%	16.0%	28.5%	24.1%	21.2%
FCF margin	36.7%	25.9%	8.0%	15.5%	14.5%	—
VALUATION
P/E	12.48	7.89	66.95	17.59	18.22	39.1
P/B	3.59	2.59	1.61	1.60	1.64	2.0
P/S	3.41	2.47	2.40	2.22	2.26	2.65
P/FCF	9.29	9.51	29.81	14.35	15.60	15.3
EV/EBITDA	9.22	6.33	21.03	9.04	11.64	17.1
EV/Revenue	3.49	2.59	3.38	2.95	3.12	3.6
Earnings yield	8.0%	12.7%	1.5%	5.7%	5.5%	2.57%
FCF yield	10.8%	10.5%	3.4%	7.0%	6.4%	6.52%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.40	1.22	0.91	1.17	1.16	1.27
Quick ratio	1.19	1.00	0.69	0.92	0.87	0.96
Debt / equity	0.48	0.36	0.80	0.76	0.78	0.74
Debt / assets	20.4%	17.7%	31.3%	31.4%	32.4%	31.4%
Net debt / EBITDA	0.19	0.30	6.08	2.24	3.21	4.61
Interest coverage	19.82	29.03	1.48	4.45	3.82	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.48	0.53	0.28	0.29	0.30	0.32
Receivables turnover	8.38	8.95	5.29	5.53	5.36	5.1
DSO (days)	44	41	69	66	68	72
DPO (days)	52	60	83	107	107	92
Cash conversion cycle	82	68	104	141	173	179
GROWTH (YoY)
Revenue growth	94.2%	23.4%	-40.6%	6.8%	-1.6%	—
Net income growth	142.7%	41.1%	-93.2%	275.8%	-3.1%	—
EPS growth	138.2%	41.7%	-93.1%	272.1%	-2.8%	—
FCF growth	157.2%	-12.9%	-81.6%	105.2%	-7.7%	—
PER SHARE ($)
EPS (diluted, TTM)	3.85	5.46	0.38	1.41	1.37	0.76
Book value / share	13.38	16.66	15.76	15.47	15.21	15.00
Revenue / share	14.09	17.47	10.55	11.16	11.01	11.18
FCF / share	5.18	4.53	0.85	1.72	1.60	1.93
Cash / share	5.39	3.96	2.25	3.59	2.39	2.05
SHAREHOLDER RETURN & SCORES
Buyback yield	0.0%	0.8%	0.0%	0.0%	0.0%	—
Altman Z-Score	3.42	3.52	1.64	2.00	1.97	2.1
Piotroski F-Score	7	6	4	7	4	7/9
Beneish M-Score	-1.90	-2.44	-2.10	-2.83	-2.71	-2.72

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	2.1	Grey zone	Grey
Income quality	3.06	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.72	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	1.03
Interest burden	0.61
Operating margin	10.8%
Asset turnover	0.31×
Financial leverage	2.34×
= ROE	5%

Growth Quality (live)	Value
Revenue stability	0.02
Earnings stability	0.33
Earnings persistence	0.50
Revenue CAGR 3y	-6.7%
EPS CAGR 3y	-41.3%
FCF CAGR 3y	1.0%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.00%

Dividend Yield5.81%

Total Shareholder Return7.07%cash yield

SBC / Revenue1.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	+33.4%
BMY	$122.1B	13.2	47%	25.6%	+3.1%	8/9	+43.8%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	+50.3%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	—
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	—
ABBV	$504.4B	80.4	-206%	21.3%	+10.4%	7/9	—
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

40 Analysts

Str Sell (0)Sell (1)Hold (23)Buy (16)Str Buy (0)

Mean Target (qtr)$30.504 targets

Target vs. Price+3.1%last-quarter mean

Next Report2026-11-03street $0.73

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$62.24B	$63.03B / $61.33B	$2.96	$3.03 / $2.89	14
FY2027	$59.79B	$61.05B / $58.17B	$2.90	$3.10 / $2.79	13
FY2028	$54.78B	$58.14B / $50.90B	$2.49	$3.03 / $1.61	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$30.50	+3.1%	2
Last Quarter	$30.50	+3.1%	4
Last Year	$28.05	-5.2%	20
All Time	$40.98	+38.5%	64

Rolling mean of published targets vs. last close $29.58. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

4/5

ROE

3/5

ROA

4/5

Debt/Eq

1/5

P/E

2/5

P/B

4/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

PFE +24.2% vs S&P 500 +15.9% — spread +8.3pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$28.34	+1.24	+4.38%	Above
SMA 50	$27.97	+1.61	+5.76%	Above
SMA 200	$26.50	+3.08	+11.62%	Above
EMA 9	$28.77	+0.81	+2.82%	Above
EMA 21	$28.39	+1.19	+4.19%	Above
EMA 50	$27.77	+1.81	+6.52%	Above
EMA 200	$26.47	+3.11	+11.75%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +8022 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%88

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago45%+55 pts since

12 Weeks Ago55%+45 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$28.34

Price vs SMA 50$27.97

Price vs SMA 200$26.50

EMA 9/21 Cross28.8/28.4

SMA 50/200Golden

ADX DirectionADX 23

Supertrend$28

Parabolic SAR$27

SMA Slope0.100

RSI69.7

Stochastic K/D87/81

StochRSI K/D99/86

Williams %R-11

CCI177

TSI vs Signal20.5

CMO39.4

ROC6.37%

OBV SignalAccum

Chaikin MF0.130

MFI53

Force Index5M

Elder Ray Bull1.36

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 81

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$29.58 / $29.74 / $30.04	S1 / S2	$29.28 / $29.12
Bollinger (20,2)	$27.18 – $29.50	Squeeze	Off
52-wk range	$23.62 – $29.88	Off 52-wk high	-1.0%
ATR (14)	$0.55 (1.9%)	Historical vol	17.3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-2.2%Jan30%

-2.2%Feb35%

+1.5%Mar52%

+0.5%Apr45%

+1.0%May50%

-1.1%Jun50%

+2.6%Jul60%

+0.1%Aug55%

-0.2%Sep55%

-0.0%Oct45%

+3.5%Nov80%

+0.5%Dec40%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	PFE	S&P 500
Weekly volatility (σ, 1y)	2.85%	1.83%
Best / worst week (1y)	+7.3% / -5.4%	—
Max drawdown (5y, monthly)	-55.1%	—
1-week VaR (95%)	-4.9%	—
Beta (5y)	0.30	1.00

PFE EQUITY WEATHER (LIVE)PARTLY CLOUDY · +24

Trend+45

Momentum+57

Volume+40

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 875 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+23.9+33.4 vs industry

Trend+45.3+49.4 vs industry

Momentum+57.1+47.2 vs industry

Volume+40.3+23.7 vs industry

Reading	PFE	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+23.9	-9.5	-24.0	-20.5
Trend	+45.3	-4.1	-25.6	-21.3
Momentum	+57.1	+9.9	-28.5	-15.8
Volume	+40.3	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
A. Bourla Chairman and Chief Executive Offic	$27.6M	54% equity+incentive
C. Boshoff Chief Scientific Officer and Pres	$10.0M	50% equity+incentive
D. Denton Chief Financial Officer, EVP	$9.7M	53% equity+incentive
A. Malik Chief U.S. Commercial Officer, EVP	$9.4M	55% equity+incentive
D. Lankler Chief Legal Officer, EVP	$9.1M	51% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	72
Social	61
Governance	68
Composite ESG	67

Composite ESG Trend

Filed	8-K contents	Items
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-06-18	Officer/Director Change; Exhibits	5.02,9.01
2026-06-18	Regulation FD	7.01
2026-05-05	Earnings Release; Exhibits	2.02,9.01
2026-04-27	Shareholder Vote	5.07
2026-02-03	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-12-16	Regulation FD Disclosure; Financial Statements and Exhibits	7.01,9.01
2025-11-21	Other Events; Financial Statements and Exhibits	8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-27 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	124 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-28 to 2026-10-15
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2026-03-27 to 2026-05-01
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Pfizer Inc. (PFE)

Institutions holding — 12 quarters

Pfizer Inc. (PFE)

Monthly Net Insider Flow (000 shares)

Signal Summary

Pfizer Inc. (PFE)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding PFE — quarterly

Institutional Put/Call — quarterly

Pfizer Inc. (PFE)

Where PFE Trades in the Dark

Pfizer Inc. (PFE)

3.8 · Employees (SEC filings)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Balance Sheet — Full

Cash Flow Statement — Full

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Street Price Target — Trajectory

Third-Party Composite Rating

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Family Scores (site weights)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)

Pfizer Inc. (PFE)